DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

16 Jan 2024


Pila Pharma and its CEO, Dorte X. Gram, has been selected to participate cost-free in a scale-up program “10 X Health” partially sponsored by the European Regional Development Fund and organised by the SmiLe Incubator and Medicon Village in Lund, Sweden.

Medicon Village and the SmiLe Incubator in Southern Sweden have – with the support of the European Regional Development Fund – initiated a scale-up program (“10 X Health”) for established, smaller life science companies to help accelerate their growth.

We’re strategically working on supporting the life-science sector in our region to support future regional economic growth. The new “10 X Health” is completely focused on our regional life science companies that have successfully passed the start-up phases and the hope is to consolidate their skills required for them to accelerate their growth further“, says Ulrika Ringdahl, Deputy CEO of Smile Incubator.

The program extends over 11 months and will cover several key topics for growth: 1) Self-assessment for scale-up, 2) Strategy, 3) People, 4) Market, 5) Digitalisation and new technologies, 6) Capital and finance, 7) Sustainability, 8) Regulatory Acceleration and 9) Ready to grow 10 X more.

CEO Dorte X. Gram comments: “I’m pleased, that Pila Pharma has been selected to be one out of seven regional life-science companies to enjoy this financial and regional support of the “10 x Health” program and the timing is really perfect. We’re currently heading towards the last small clinical trial with XEN-D0501 in obese persons with diabetes, before we will enter a phase with bigger clinical studies with a need to scale-up our business”.

Malmö, 16 January 2024

For more information:

Dorte X. Gram, CEO
Text: +46 (0)73 903 6969
Mail: dxg@pilapharma.com

Pila Pharma’s share ticker PILA is subject to trade on Nasdaq First North Growth Market, Sweden with Aqurat Fondkommission AB as Certified Adviser.
Contact: M: ca@aqurat.se – T: +46 (0)8 684 05 800

    If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact ps@danskbiotek.dk or +45 7172 1114

    Copyright 2024 DANISH BIO – DANSK BIOTEK. All rights reserved.